Researchers continue to excited about this new drug, a groundbreaking dual agonist showing remarkable data in initial trials for body management. It acts by targeting two hormones : GLP-1 and GIP, that , when activated , support influence hunger and improve energy expenditure . Preliminary reports demonstrate substantial weight reduction and likely